FDA Letter API

City Vapes Premium eJuice Inc.

Letter data

Company
City Vapes Premium eJuice Inc.
Recipient
City Vapes Premium eJuice Inc. | United States | sales@cityvapes.com | doitbyecig@shaw.ca
Issue date
2020-10-22
Posted date
Not available
FDA office
Center for Tobacco Products
Subject
Not available
Product
Not available
CMS ID
604021
Reference number
RW1901231
FEI
Not available
Inspection dates
Not available

Normalized citations

21 CFR: None found

21 U.S.C.: None found

Related FDA links

No related FDA letter link is present in the source index.

Full source text

CLOSEOUT LETTER City Vapes Premium eJuice Inc. MARCS-CMS 604021 — October 22, 2020 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA Electronic Mail Reference #: RW1901231 Recipient: City Vapes Premium eJuice Inc. United States sales@cityvapes.com doitbyecig@shaw.ca Issuing Office: Center for Tobacco Products United States The United States Food and Drug Administration’s (FDA) Center for Tobacco Products has completed an evaluation of your corrective actions in response to our Warning Letter dated February 28, 2020. Based on our evaluation, it appears that you have taken steps to address the violation contained in the Warning Letter for the website https://cityvapes.com. This letter does not relieve you or your firm from the responsibility of taking all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. This letter also will not preclude any regulatory action should violations be observed in the future. Sincerely, /S/ David Rice Branch Chief Division of Promotion, Advertising, and Labeling Office of Compliance and Enforcement Center for Tobacco Products Content current as of: 10/26/2020